Trials / Completed
CompletedNCT03982394
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,759 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
Conditions
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2025-09-02
- Completion
- 2025-09-02
- First posted
- 2019-06-11
- Last updated
- 2025-11-17
Locations
302 sites across 21 countries: Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Source: ClinicalTrials.gov record NCT03982394. Inclusion in this directory is not an endorsement.